文献
J-GLOBAL ID:202202246202195402
整理番号:22A0910319
全生存のための代替試験エンドポイントとしての無進行生存2の妥当性【JST・京大機械翻訳】
The validity of progression-free survival 2 as a surrogate trial end point for overall survival
著者 (10件):
Woodford Rachel G.
(National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia)
,
Woodford Rachel G.
(St George Cancer Care Centre, Sydney, New South Wales, Australia)
,
Zhou Deborah D.-X.
(Chris O’Brien Lifehouse, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia)
,
Kok Peey-Sei
(National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia)
,
Lord Sally J.
(National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia)
,
Friedlander Michael
(Nelune Cancer Centre, Prince of Wales Hospital and Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia)
,
Marschner Ian C.
(National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia)
,
Simes R. John
(National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia)
,
Lee Chee Khoon
(National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia)
,
Lee Chee Khoon
(St George Cancer Care Centre, Sydney, New South Wales, Australia)
資料名:
Cancer (Hoboken, N.J.)
(Cancer (Hoboken, N.J.))
巻:
128
号:
7
ページ:
1449-1457
発行年:
2022年
JST資料番号:
D0781B
ISSN:
0008-543X
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
アメリカ合衆国 (USA)
言語:
英語 (EN)